慢性静脉阻塞治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Chronic Venous Occlusions Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月20日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球慢性静脉阻塞治疗市场价值为 66 亿美元，预计 2024-2032 年复合年增长率为 5.0%。市场是由意识增强和技术进步所推动的。慢性静脉功能不全（CVI）和深部静脉栓塞（DVT）等慢性静脉疾病的盛行率不断上升，增加了有效治疗的需求。静脉注射雷射治疗 (EVLT) 和射频消融 (RFA) 等微创手术由于恢復时间更快、风险更低而越来越受欢迎。双功超音波等先进影像技术提高了诊断准确性和治疗计划。个人化医疗正在推动客製化疗法的发展，提高治疗效果和病患照护。

整个慢性静脉阻塞治疗产业根据产品、应用、最终用途和地区进行分类。

该市场分为设备和药品，预计到 2032 年，药品市场将超过 51 亿美元。抗生素是治疗 CVI 引起的溃疡和皮肤感染的首选药物。直接口服抗凝血剂 (DOAC) 的兴起提高了安全性和便利性，推动了其采用。支持药物报销和取得的政府和医疗保健政策进一步促进了市场成长。研发投资的增加正在加速新药的推出并解决未满足的医疗需求。

市场也按应用细分，包括深部静脉栓塞、水肿、静脉瘀血性溃疡、静脉曲张等应用。到 2032 年，水肿领域预计将超过 29 亿美元。导致水肿的心臟衰竭、肾臟疾病和静脉功能不全等疾病的普遍存在，增加了对有效治疗的需求。利尿剂和抗发炎药物等药物治疗的进步正在改善管理和治疗结果。人口老化和创新药物配方正在推动细分市场的扩张。

2023年，北美慢性静脉闭塞治疗市场收入达27亿美元，预计将强劲成长。慢性静脉疾病的高盛行率、先进的医疗基础设施和微创手术是关键驱动因素。政府透过有利的报销政策和医疗保险覆盖范围提供的支持正在扩大获得先进治疗的机会。持续的研发投资正在促进创新和新疗法的推出，以巩固北美作为市场领导者的地位。

产业生态系统分析
产业影响力
- 成长动力
  - 静脉曲张盛行率不断增加，人们对其治疗的认识不断提高
  - 人们越来越偏好微创手术
  - 骨科手术数量增加
  - 慢性静脉功能不全治疗的技术进步
- 产业陷阱与挑战
  - 不同治疗模式相关的副作用与风险
  - 严格的监管指引
成长潜力分析
监管环境
报销场景
治疗景观
未来市场趋势
技术景观
流行病学情景
波特的分析
PESTEL分析
差距分析

第 4 章：竞争格局

介绍
公司矩阵分析
公司市占率分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

主要趋势
装置
- 压缩装置
- 静脉内消融
  - 雷射烧蚀
  - 射频消融术
- 硬化疗法
- 静脉剥离器
- 其他设备
药品
- 止痛药
- 抗生素
- 抗凝血剂
- 其他药品

第 6 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
静脉曲张
静脉淤滞性溃疡
浮肿
深层静脉栓塞
其他应用

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
门诊手术中心
其他最终用户

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

3M Company
Bayer AG
Boston Scientific Corporation
Candela
ConvaTec Inc.
Fotona
Julius Zorn GmbH
Leucadia Pharmaceuticals (Hikma)
Medi GmbH and Co. KG
Medtronic plc
Merz Pharma
Pfizer Inc.
Sanofi
Sciton, Inc
Tactile Medical
Venclose, Inc. (Becton Dickinson and Company)
Viatris Inc.

简介目录

Product Code: 5398

The Global Chronic Venous Occlusions Treatment Market was valued at USD 6.6 billion in 2023 and is projected to grow at a CAGR of 5.0% from 2024-2032. The market is driven by increased awareness and technological advancements. The rising prevalence of chronic venous diseases like chronic venous insufficiency (CVI) and deep vein thrombosis (DVT) is boosting demand for effective treatments. Minimally invasive procedures, such as endovenous laser therapy (EVLT) and radiofrequency ablation (RFA), are gaining popularity due to faster recovery times and lower risks. Advanced imaging technologies like duplex ultrasound have improved diagnostic accuracy and treatment planning. Personalized medicine is driving the development of tailored therapies, enhancing treatment efficacy and patient care.

The overall chronic venous occlusions treatment industry is classified based on the product, application, end use , and region.

The market is segmented into devices and drugs, with the drugs segment projected to surpass USD 5.1 billion by 2032. Various drugs, including analgesics, antibiotics, and anticoagulants, are used in diagnosis and therapy. Antibiotics are preferred for treating ulcers and skin infections from CVI. The rise of direct oral anticoagulants (DOACs) offers improved safety and convenience, driving their adoption. Government and healthcare policies supporting drug reimbursement and access are further bolstering market growth. Increased R&D investments are accelerating the introduction of new drugs and addressing unmet medical needs.

The market is also segmented by application, including deep vein thrombosis, edema, venous stasis ulcers, varicose veins, and other applications. The edema segment is expected to exceed USD 2.9 billion by 2032. The prevalence of conditions like heart failure, kidney disease, and venous insufficiency, which lead to edema, is increasing demand for effective treatments. Advances in pharmacological therapies, such as diuretics and anti-inflammatory drugs, are improving management and treatment outcomes. The aging population and innovative drug formulations are driving segment expansion.

In 2023, North America accounted for USD 2.7 billion in revenue from the chronic venous occlusion's treatment market, with robust growth projected. The high prevalence of chronic venous diseases, advanced healthcare infrastructure, and minimally invasive procedures are key drivers. Government support through favorable reimbursement policies and health insurance coverage is broadening access to advanced treatments. Ongoing R&D investments are fostering innovation and the introduction of new therapies, solidifying North America's position as a market leader.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of varicose veins coupled with rising awareness regarding its treatment
  - 3.2.1.2 Growing preference for minimally invasive procedures
  - 3.2.1.3 Rise in number of orthopedic procedures
  - 3.2.1.4 Technological advancements pertaining to chronic venous insufficiency treatment therapies
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Side effects and risks associated with different treatment modes
  - 3.2.2.2 Strict regulatory guidelines
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Treatment landscape
3.7 Future market trends
3.8 Technological landscape
3.9 Epidemiology scenario
3.10 Porter's analysis
3.11 PESTEL analysis
3.12 Gap analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Devices
- 5.2.1 Compression devices
- 5.2.2 Endovenous ablation
  - 5.2.2.1 Laser ablation
  - 5.2.2.2 Radiofrequency ablation
- 5.2.3 Sclerotherapy
- 5.2.4 Vein stripper
- 5.2.5 Other devices
5.3 Drugs
- 5.3.1 Analgesics
- 5.3.2 Antibiotics
- 5.3.3 Anticoagulants
- 5.3.4 Other drugs

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Varicose veins
6.3 Venous stasis ulcers
6.4 Edema
6.5 Deep vein thrombosis
6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Ambulatory surgical centers
7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa